Fierce Biotech May 16, 2024
After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a breakthrough designation from the FDA.
The company’s DNA-based blood test for infectious diseases, designed to detect more than 1,000 pathogens from a single sample, is getting a boost at the agency toward helping manage immunocompromised patients suspected of threatening lung conditions.
The Karius Test has been commercially available since 2017 as a lab-developed test, and the company has said it is currently being employed at about 400 nationwide locations—largely at cancer centers, where patients may have heightened risks of respiratory infections and pneumonia from bacteria, fungi, parasites and viruses.
Karius has estimated that about 60% of deaths among...
Today's Sponsors
Today's Sponsor